• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2012 - 2019年美国数据库中2型糖尿病患者糖化血红蛋白和体重指数的变化趋势

Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012-2019.

作者信息

Boye Kristina S, Lage Maureen J, Shinde Shraddha, Thieu Vivian, Bae Jay Patrick

机构信息

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.

HealthMetrics Outcomes Research, 27576 River Reach Drive, Bonita Springs, FL, 34134, USA.

出版信息

Diabetes Ther. 2021 Jul;12(7):2077-2087. doi: 10.1007/s13300-021-01084-0. Epub 2021 Jun 2.

DOI:10.1007/s13300-021-01084-0
PMID:34076849
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8266935/
Abstract

INTRODUCTION

Given the high rates of obesity and poor glycemic control among individuals with type 2 diabetes (T2D), this study examines current trends in HbA1c and body mass index (BMI) as well as the association between HbA1c and BMI among adults with T2D.

METHODS

Data from the IBM® MarketScan® Explorys® Claims-EMR Data were used to construct eight annual cohorts for the years 2012-2019. Each annual cohort included adults identified with T2D who had at least one recorded HbA1c laboratory result and BMI value in the year of interest. Given these cohorts, trends in HbA1c and BMI were described over time using generalized estimating equation (GEE) tests.

RESULTS

Results indicate that, over the study period from 2012-2019, average BMI increased significantly and there was a decrease in the percentage of adults with T2D who achieved glycemic control. In addition, for all years, higher BMI classification was associated with higher HbA1c values. When examining results for patients in different age groups, the findings were generally consistent with the overall population. In each age group, but most notably the age 18-44 group, the mean BMI increased over time and higher BMI was associated with higher HbA1c.

CONCLUSION

Given the increase in BMI and decreasing percentage of individuals achieving glycemic control among adults with T2D found over the study period, therapies which decrease BMI as well as HbA1c can potentially have a significant impact on the management of T2D. The growing proportion of the younger age group with higher mean BMI may remain a key subgroup of interest.

摘要

引言

鉴于2型糖尿病(T2D)患者中肥胖率高且血糖控制不佳,本研究调查了糖化血红蛋白(HbA1c)和体重指数(BMI)的当前趋势,以及成年T2D患者中HbA1c与BMI之间的关联。

方法

使用来自IBM® MarketScan® Explorys® 理赔电子病历数据构建2012 - 2019年的八个年度队列。每个年度队列包括确诊为T2D的成年人,他们在感兴趣的年份至少有一次记录的HbA1c实验室结果和BMI值。基于这些队列,使用广义估计方程(GEE)检验描述HbA1c和BMI随时间的趋势。

结果

结果表明,在2012 - 2019年的研究期间,平均BMI显著增加,实现血糖控制的T2D成年患者百分比下降。此外,在所有年份中,较高的BMI分类与较高的HbA1c值相关。在检查不同年龄组患者的结果时,这些发现与总体人群基本一致。在每个年龄组中,但最显著的是18 - 44岁组,平均BMI随时间增加,较高的BMI与较高的HbA1c相关。

结论

鉴于在研究期间发现成年T2D患者中BMI增加且实现血糖控制的个体百分比下降,降低BMI以及HbA1c的疗法可能对T2D的管理产生重大影响。平均BMI较高的年轻年龄组比例不断增加可能仍然是一个关键的关注亚组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9e/8266935/82c6adbeba78/13300_2021_1084_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9e/8266935/d6b8fbe2b45b/13300_2021_1084_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9e/8266935/3fef4d34830f/13300_2021_1084_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9e/8266935/82c6adbeba78/13300_2021_1084_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9e/8266935/d6b8fbe2b45b/13300_2021_1084_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9e/8266935/3fef4d34830f/13300_2021_1084_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe9e/8266935/82c6adbeba78/13300_2021_1084_Fig3_HTML.jpg

相似文献

1
Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012-2019.2012 - 2019年美国数据库中2型糖尿病患者糖化血红蛋白和体重指数的变化趋势
Diabetes Ther. 2021 Jul;12(7):2077-2087. doi: 10.1007/s13300-021-01084-0. Epub 2021 Jun 2.
2
Trends of HbA1c and BMI in People with Type 2 Diabetes: A Japanese Claims-Based Study.2型糖尿病患者糖化血红蛋白(HbA1c)和体重指数(BMI)的变化趋势:一项基于日本医保理赔数据的研究
Diabetes Ther. 2024 Apr;15(4):801-817. doi: 10.1007/s13300-024-01543-4. Epub 2024 Feb 24.
3
Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data.美国2型糖尿病患者的肥胖与血糖控制:一项使用保险理赔数据的回顾性队列研究。
J Diabetes Complications. 2021 Sep;35(9):107975. doi: 10.1016/j.jdiacomp.2021.107975. Epub 2021 Jun 19.
4
Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.在美国现实临床实践中,2型糖尿病患者使用基础胰岛素实现血糖控制的概率
Diabetes Ther. 2018 Jun;9(3):1347-1358. doi: 10.1007/s13300-018-0413-5. Epub 2018 Mar 29.
5
The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis.糖化血红蛋白(HbA1c)与1年糖尿病相关医疗费用之间的关联:一项回顾性索赔数据库分析。
Diabetes Ther. 2022 Feb;13(2):367-377. doi: 10.1007/s13300-022-01212-4. Epub 2022 Feb 7.
6
Glycemic Control and Obesity Among People With Type 2 Diabetes in Europe and Australia: A Retrospective Cohort Analysis.欧洲和澳大利亚2型糖尿病患者的血糖控制与肥胖:一项回顾性队列分析。
Diabetes Ther. 2024 Jun;15(6):1435-1449. doi: 10.1007/s13300-024-01583-w. Epub 2024 Apr 29.
7
Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysis.1987年至2022年2型糖尿病随机安慰剂对照试验中基线糖化血红蛋白和体重指数的趋势:一项系统评价和荟萃分析
EClinicalMedicine. 2023 Feb 16;57:101868. doi: 10.1016/j.eclinm.2023.101868. eCollection 2023 Mar.
8
An Economic Evaluation of the Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study.2型糖尿病成人血糖控制与总医疗费用关系的经济评估:回顾性队列研究
Diabetes Ther. 2024 Feb;15(2):395-407. doi: 10.1007/s13300-023-01507-0. Epub 2023 Dec 1.
9
Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study.2型糖尿病患者口服降糖药的失效时间:一项回顾性队列研究。
Diabetes Ther. 2021 May;12(5):1463-1474. doi: 10.1007/s13300-021-01051-9. Epub 2021 Apr 10.
10
Impact of Weight Change on Glycemic Control and Metabolic Parameters in T2D: A Retrospective US Study Based on Real-World Data.体重变化对2型糖尿病患者血糖控制及代谢参数的影响:一项基于美国真实世界数据的回顾性研究
Diabetes Ther. 2024 Feb;15(2):409-426. doi: 10.1007/s13300-023-01511-4. Epub 2023 Dec 1.

引用本文的文献

1
Prevalence, awareness, treatment, and control of prediabetes and diabetes mellitus in older adults: findings from Iranian STEPS surveys (2016 and 2021).老年人糖尿病前期和糖尿病的患病率、知晓率、治疗率及控制率:伊朗STEPS调查(2016年和2021年)的结果
BMC Public Health. 2025 Aug 5;25(1):2658. doi: 10.1186/s12889-025-23654-8.
2
Time Trends of Body Mass Index and its Impact on Glycemic Control Among Finnish Patients with Type 2 Diabetes.芬兰2型糖尿病患者体重指数的时间趋势及其对血糖控制的影响
Diabetes Ther. 2025 Jun 16. doi: 10.1007/s13300-025-01763-2.
3
Glycaemic and Weight Control in People Aged 65 or Younger Newly Diagnosed with Type 2 Diabetes in Spain: Insights from the PRIORITY-T2D Study.

本文引用的文献

1
8. Obesity Management for the Treatment of Type 2 Diabetes: .8. 肥胖症管理用于 2 型糖尿病的治疗: 。
Diabetes Care. 2020 Jan;43(Suppl 1):S89-S97. doi: 10.2337/dc20-S008.
2
6. Glycemic Targets: .6. 血糖目标: 。
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. doi: 10.2337/dc20-S006.
3
Diabetes: the place of new therapies.糖尿病:新疗法的地位
西班牙65岁及以下新诊断2型糖尿病患者的血糖和体重控制:PRIORITY-T2D研究的见解
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03230-7.
4
Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review.2型糖尿病早期有效血糖和体重管理的研究进展:一项叙述性综述
Diabetes Obes Metab. 2025 Apr;27(4):1708-1718. doi: 10.1111/dom.16206. Epub 2025 Jan 28.
5
Impact of Rice Bran Oil Emulsified Formulation on Digestion and Glycemic Response to Japonica Rice: An In Vitro Test and a Clinical Trial in Adult Men.米糠油乳化制剂对粳稻消化及血糖反应的影响:一项针对成年男性的体外试验和临床试验
Foods. 2024 Aug 21;13(16):2628. doi: 10.3390/foods13162628.
6
BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 SOPHIA study.2型糖尿病临床试验及真实世界环境中的BMI变异性与心血管结局:IMI2 SOPHIA研究
Cardiovasc Diabetol. 2024 Jul 16;23(1):256. doi: 10.1186/s12933-024-02299-8.
7
Glycemic Control and Obesity Among People With Type 2 Diabetes in Europe and Australia: A Retrospective Cohort Analysis.欧洲和澳大利亚2型糖尿病患者的血糖控制与肥胖:一项回顾性队列分析。
Diabetes Ther. 2024 Jun;15(6):1435-1449. doi: 10.1007/s13300-024-01583-w. Epub 2024 Apr 29.
8
Trajectories of Body Mass Index and Risk for Diabetes Complications and All-Cause Mortality in Finnish Type 2 Diabetes Patients.芬兰2型糖尿病患者体重指数轨迹与糖尿病并发症及全因死亡率风险
Clin Epidemiol. 2024 Mar 29;16:203-212. doi: 10.2147/CLEP.S450455. eCollection 2024.
9
Trends of HbA1c and BMI in People with Type 2 Diabetes: A Japanese Claims-Based Study.2型糖尿病患者糖化血红蛋白(HbA1c)和体重指数(BMI)的变化趋势:一项基于日本医保理赔数据的研究
Diabetes Ther. 2024 Apr;15(4):801-817. doi: 10.1007/s13300-024-01543-4. Epub 2024 Feb 24.
10
Characteristics, glycemic control and outcomes of adults with type-2 diabetes mellitus attending specialized clinics in primary healthcare centers in Bahrain-A cross-sectional study.巴林初级医疗中心专科诊所2型糖尿病成年患者的特征、血糖控制及结局——一项横断面研究
J Family Med Prim Care. 2023 Nov;12(11):2576-2583. doi: 10.4103/jfmpc.jfmpc_829_23. Epub 2023 Nov 21.
Ther Adv Endocrinol Metab. 2018 Oct 30;10:2042018818807599. doi: 10.1177/2042018818807599. eCollection 2019.
4
A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.甘精胰岛素与利司那肽固定比例复方制剂的安全性及不良事件概述
Diabetes Ther. 2019 Feb;10(1):21-33. doi: 10.1007/s13300-018-0547-5. Epub 2018 Dec 11.
5
Epidemiology of Obesity in Adults: Latest Trends.成人肥胖的流行病学:最新趋势。
Curr Obes Rep. 2018 Dec;7(4):276-288. doi: 10.1007/s13679-018-0317-8.
6
Treatment patterns and clinical characteristics of patients with type 2 diabetes mellitus according to body mass index: findings from an electronic medical records database.根据体重指数分析2型糖尿病患者的治疗模式及临床特征:来自电子病历数据库的研究结果
BMJ Open Diabetes Res Care. 2017 May 27;5(1):e000382. doi: 10.1136/bmjdrc-2016-000382. eCollection 2017.
7
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes.在 2 型糖尿病患者的减肥试验中,体重减轻对糖化血红蛋白的影响。
Diabetes Obes Metab. 2017 Sep;19(9):1295-1305. doi: 10.1111/dom.12971. Epub 2017 May 22.
8
Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009-2011.糖尿病患者的肥胖与血糖控制:对2009 - 2011年美国医生电子健康记录的分析
J Diabetes Complications. 2016 Mar;30(2):212-20. doi: 10.1016/j.jdiacomp.2015.11.016. Epub 2015 Nov 17.
9
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.2015年2型糖尿病高血糖管理:以患者为中心的方法:美国糖尿病协会和欧洲糖尿病研究协会立场声明更新版
Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441.
10
Excess body weight affects HbA1c progression irrespective of baseline HbA1c levels in Japanese individuals: a longitudinal retrospective study.超重影响日本个体的糖化血红蛋白(HbA1c)进展,与基线HbA1c水平无关:一项纵向回顾性研究。
Endocr Res. 2015;40(2):63-9. doi: 10.3109/07435800.2014.934962. Epub 2014 Aug 11.